mRNA Cancer Vaccine Cuts Melanoma Return in 1,137 Patients

For the first time, scientists have proven that mRNA technology can fight cancer just as effectively as it fought COVID-19.

Drugmakers Merck and Moderna announced Wednesday that their personalized melanoma treatment successfully reduced tumor recurrence in a major trial involving 1,137 patients. The drug, called intismeran autogene, combines the same mRNA science behind COVID vaccines with a cutting-edge approach that targets each patient's unique cancer fingerprint.

The year-long trial delivered clear results. Two-thirds of participants received the new mRNA treatment plus pembrolizumab, the current standard drug, while the rest received pembrolizumab alone. Those who got the combination treatment showed significantly better outcomes in preventing their melanoma from returning after surgery.

Here's how the treatment works: doctors take a sample of the patient's tumor and analyze its unique mutational signature. Then they use mRNA technology to create customized molecular instructions that train the patient's immune system to recognize and attack that specific cancer.

The technology behind this breakthrough has been decades in the making. While mRNA vaccines gained fame during the pandemic, researchers have been working quietly to apply the same approach to cancer treatment. Wednesday's announcement represents the first time these efforts have succeeded in a large-scale trial.

The Ripple Effect

This success extends far beyond melanoma patients. Moderna CEO Stephane Bancel called it "an extraordinary milestone for mRNA science and, most importantly, for patients with cancer." The company is already testing the treatment against lung, bladder, and kidney cancers.

Oxford oncologist Lennard Lee, who wasn't involved in the trial, called the results "very encouraging." Marco Gerlinger, a professor at London's Barts Cancer Institute, went further, calling it "proof of principle that personalized cancer vaccines work" and "a breakthrough in the development of new cancer immunotherapies."

The stock market responded with enthusiasm. Moderna's shares jumped 145 percent while Merck's climbed more than 12 percent, reflecting investor confidence in the technology's potential.

Melanoma ranks among the deadliest forms of skin cancer, with more than 330,000 new cases diagnosed worldwide in 2022. This treatment offers new hope to patients facing a disease that has historically been difficult to prevent from returning.

The companies plan to present their complete data at an upcoming international conference and will begin filing with regulators for approval. If approved, this could become the first personalized mRNA cancer treatment available to patients.

The same technology that helped end a pandemic is now opening new doors in the fight against cancer.